Littérature scientifique sur le sujet « Response to therapies »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Response to therapies ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Response to therapies"
Gayan, Chathura. « Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies ». Cancer Research and Cellular Therapeutics 2, no 1 (28 mars 2018) : 01–08. http://dx.doi.org/10.31579/2640-1053/022.
Texte intégralDudekula, Noor, Vikas Arora, Zsuzsanna Callaerts-Vegh et Richard A. Bond. « The Temporal Hormesis of Drug Therapies ». Dose-Response 3, no 3 (1 mai 2005) : dose—response.0. http://dx.doi.org/10.2203/dose-response.003.03.009.
Texte intégralTruelove, Edmond, Kimberly Hanson Huggins, Lloyd Mancl et Samuel F. Dworkin. « NONSPLINT THERAPIES : Authors' response ». Journal of the American Dental Association 137, no 11 (novembre 2006) : 1493–94. http://dx.doi.org/10.14219/jada.archive.2006.0070.
Texte intégralPrasad, Vinay, Victoria Kaestner et Alyson Haslam. « Bridging therapies used in trials testing CAR-T therapies. » Journal of Clinical Oncology 42, no 16_suppl (1 juin 2024) : e19011-e19011. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e19011.
Texte intégralBrown, Barbara G. « Innovative Therapies : Biological Response Modifiers ». Journal of the Association of Pediatric Oncology Nurses 5, no 1-2 (janvier 1988) : 26. http://dx.doi.org/10.1177/104345428800500109.
Texte intégralMattison, Lars, et Paul Iaizzo. « PHRENIC NERVE RESPONSE TO CRYOABLATION THERAPIES ». Journal of the American College of Cardiology 65, no 10 (mars 2015) : A405. http://dx.doi.org/10.1016/s0735-1097(15)60405-3.
Texte intégralCunningham, Jonathan W., et Peder L. Myhre. « NT-proBNP Response to Heart Failure Therapies ». Journal of the American College of Cardiology 78, no 13 (septembre 2021) : 1333–36. http://dx.doi.org/10.1016/j.jacc.2021.07.045.
Texte intégralGerger, Armin, Melissa LaBonte et Heinz-Josef Lenz. « Molecular Predictors of Response to Antiangiogenesis Therapies ». Cancer Journal 17, no 2 (mars 2011) : 134–41. http://dx.doi.org/10.1097/ppo.0b013e318212db3c.
Texte intégralHeld, Barbara S. « Common dances, uncommon therapies : Response to Ryder. » Journal of Family Psychology 1, no 4 (1988) : 476–79. http://dx.doi.org/10.1037/h0084983.
Texte intégralJohnston, Stephen R. D., Alexandra Leary, Lesley-Ann Martin, Ian E. Smith et Mitch Dowsett. « Enhancing endocrine response with novel targeted therapies ». Cancer 112, S3 (2008) : 710–17. http://dx.doi.org/10.1002/cncr.23190.
Texte intégralThèses sur le sujet "Response to therapies"
Massó, Vallés Daniel. « Inhibiting Myc and the Myc dependent inflammatory response as cancer therapies ». Doctoral thesis, Universitat Autònoma de Barcelona, 2017. http://hdl.handle.net/10803/458137.
Texte intégralThe work of this thesis was carried out in the Mouse Models of Cancer Therapies Laboratory led by Dr. Laura Soucek in the Preclinical Research Program of the Vall d’Hebron Institute of Oncology (VHIO), and comprises two differentiated parts centered on two oncogenic functions of Myc. In the first project we validated the pharmacological inhibition of mast cells as a therapeutic strategy against pancreatic ductal adenocarcinoma (PDAC). To do so, we made use of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in mouse models of PDAC, the most common and aggressive pancreatic tumor. Treatment with ibrutinib inhibited mast cell degranulation, reduced cell proliferation and leukocytic infiltration in the tumor stroma and dramatically reduced collagen deposition. In fibrotic mouse models of PDAC, both genetically-engineered and patient-derived, ibrutinib extended survival and synergized with chemotherapy, demonstrating the clinical applicability of this drug against pancreatic cancer. This project has led to the publication of a research paper and an editorial (Masso-Valles et al. 2015; Masso-Valles et al. 2016), as well as contributing to the initiation of clinical trials combining ibrutinib with chemotherapy in patients with metastatic PDAC (phase 1/2: NCT02562898 and phase 2/3: NCT02436668). The second project is focused on the relationship between Myc and metastasis. We studied de potential of Omomyc, a Myc dominant negative mutant that had shown extraordinary efficacy against primary tumors in multiple mouse models, against metastatic breast cancer. We demonstrated that Myc inhibition by Omomyc is a safe and effective therapy against breast cancer by impairing cell proliferation, angiogenesis, migration and invasion in vitro, dramatically reducing primary tumor and metastatic growth in immunocompromised mice, even eradicating established metastases, and preventing primary tumor and metastatic formation almost completely in immunocompetent mice. Thus, we have demonstrated for the first time the applicability of Omomyc against metastasis, challenging the pre-established notion that Myc inhibition could potentiate, rather than inhibit, invasion. Finally, we have validated TMTP1-Omomyc as the first direct-deliverable Omomyc-based drug for the treatment of metastatic triple negative breast cancer, providing a new therapeutic opportunity for patients suffering from this dreadful and incurable disease.
FATIMA, RIZWAN NARJIS. « Targeting the integrated stress response (ISR) as a therapeutic option for chronic lymphocytic leukemia ». Thesis, The University of Sydney, 2021. https://hdl.handle.net/2123/25009.
Texte intégralNji, Akindeh Mbuh. « Modeling response and delayance to parasite clearance time to artemisinin combination therapies(ACT) ». Diss., Ludwig-Maximilians-Universität München, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-168213.
Texte intégralRandall, Adrian Joseph. « A systems approach to uncovering the adaptive response of cancer to targeted therapies ». Thesis, Massachusetts Institute of Technology, 2012. http://hdl.handle.net/1721.1/72967.
Texte intégralCataloged from PDF version of thesis.
Includes bibliographical references (p. 47-53).
Tyrosine kinase inhibitors have significant promise in the fight to develop agents that can target cancer in a tumor-specific manner. A number of drugs have been and are currently in development to inhibit specific kinases that can mediate uncontrolled proliferation; however, an unfortunate eventuality for most patients receiving these treatments is the development of resistance that renders these drugs almost completely ineffective. While a number of mechanisms can evolve within a tumor to mitigate effects of kinase inhibitors, we sought to uncover what changes are occurring in the tyrosine phosphorylation network at both short timescales (minutes to 72 hours) and long timescales (120 hours+) that can be playing a role in helping a tumor become resistant to driver-kinase inhibition. It is our hypothesis that specific feedback networks are able to detect and overcome driver kinase inhibition through activation of potential other pathways, which can go on to mediate a longer term resistance phenotype. In order to probe dynamics in the tyrosine phosphorylation network, we employed mass spectrometry to analyze peptides derived from six non-small cell lung cancer cell lines that we classify as either EGFR+ or EML4-ALK+. From both mass spectrometry data and growth assays, we identified an unintuitive boost in signaling and growth in response to low inhibitor concentrations, suggestive of a cellular mechanism that is adaptive to driver kinase inhibition. Studies of EML4-ALK driven H3122 cells showed that this short-term response is not the same as the known long-term resistance mechanism to ALK inhibition, leading support to the notion that the short-term "adaptive response" may be a novel type of mechanism to aid tumor adaptation to targeted therapies. In an effort to better probe signaling events occurring downstream of the phosphotyrosine network, a new pull down technique for mass spectrometry using 14-3-3 protein against phosphoserine and phosphothreonine peptides is described. The results of these studies open up many potential avenues for further exploration into the immediate and long-term signaling response of cancer to targeted therapies.
by Adrian Joseph Randall.
S.M.
Breen, Michael Scott. « TISSUE RESPONSE TO INTERVENTIONAL MRI-GUIDED THERMAL ABLATION THERAPY ». Case Western Reserve University School of Graduate Studies / OhioLINK, 2004. http://rave.ohiolink.edu/etdc/view?acc_num=case1080938405.
Texte intégralReddy, Papari Prashanth. « Non-motor symptoms in advanced Parkinson's : the natural history and response to advanced therapies ». Thesis, King's College London (University of London), 2015. http://kclpure.kcl.ac.uk/portal/en/theses/nonmotor-symptoms-in-advanced-parkinsons(b82ce682-b4f0-424d-9c7e-9f293b11bc18).html.
Texte intégralFenton, Audrey C. « The role of oncogenic kras as a determinant of response to EGER?HER2 targeted therapies ». Thesis, Queen's University Belfast, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.534743.
Texte intégralCramer, Megan L. « Novel signaling pathways in skeletal muscle : Modifiers of disease and the immune response to therapies ». The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1531790292235549.
Texte intégralMcNally, Jonathan P. « The rational targeting of the DNA damage response pathway for the selective elimination of encephalitogenic T cells ». University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1428652709.
Texte intégralBeshir, Kahlid Bushra. « Genetic polymorphisms in 'Plasmodium falciparum' associated with reduced response to artemisinin combination therapies in Western Kenya ». Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.558359.
Texte intégralLivres sur le sujet "Response to therapies"
Janusz, Rak, dir. Oncogene-directed therapies. Totowa, N.J : Humana Press, 2003.
Trouver le texte intégralLoes, Michael, et Michael W. Loes. The healing response. Topanga, Calif : Freedom Press, 2002.
Trouver le texte intégralCastro, Antonio de Miguel. Clopidogrel response in acute coronary syndrome : Clinical implications and emerging therapies. Hauppauge, N.Y : Nova Science Publishers, 2010.
Trouver le texte intégralA, Foon Kenneth, et Muss Hyman B, dir. Biological and hormonal therapies of cancer. Boston : Kluwer Academic Publishers, 1998.
Trouver le texte intégralL, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging. et International Symposium on Combination Therapies (1st : 1991 : Washington, D.C.), dir. Combination therapies : Biological response modifiers in the treatment of cancer and infectious diseases. New York : Plenum Press, 1992.
Trouver le texte intégralL, Goldstein Allan, Garaci E, Institute for Advanced Studies in Immunology & Aging. et International Symposium on Combination Therapies (2nd : 1992 : Acireale, Italy), dir. Combination therapies 2 : Biological response modifiers in the treatment of cancer and infectious diseases. New York : Plenum Press, 1993.
Trouver le texte intégralHoward, Brody. The placebo response : How you can release the body's inner pharmacy for better health. New York : Cliff Street Books, 2000.
Trouver le texte intégralValentine, Tom. Applied kinesiology : Muscle response in diagnosis, therapy and preventive medicine. Rochester, Vt : Thorsons Publishers, 1987.
Trouver le texte intégralValentine, Tom. Applied kinesiology : Muscle response in diagnosis, therapy, and preventive medicine. Rochester, Vt : Healing Arts Press, 1987.
Trouver le texte intégralThe placebo response and the power of unconscious healing. New York : Routledge, 2008.
Trouver le texte intégralChapitres de livres sur le sujet "Response to therapies"
Hsia, Judith, et Ting Tang. « Aspirin as a Biological Response Modifier ». Dans Combination Therapies, 131–37. Boston, MA : Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_16.
Texte intégralCassone, Antonio, Antonella Torosantucci, Carla Palma, Maria J. Gomez, Clara M. Ausiello et Julie Y. Djeu. « Cell Wall Constituents of Candida Albicans as Biological Response Modifiers ». Dans Combination Therapies, 159–66. Boston, MA : Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_19.
Texte intégralVenditti, Adriano, Maria Teresa Scimo, Giovanni Del Poeta, Roberto Stasi, Ugo Coppetelli, Mario Masi, Manrico Cecconi et al. « Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes ». Dans Combination Therapies 2, 171–77. Boston, MA : Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_20.
Texte intégralKirkley, J. E., Paul H. Naylor, Dante J. Marciani, Charlotte R. Kensil, Mark Newman et A. L. Goldstein. « QS-21 Augments the Antibody Response to a Synthetic Peptide Vaccine Compared to Alum ». Dans Combination Therapies, 231–36. Boston, MA : Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_28.
Texte intégralNakanishi, Toshio. « Thromboembolism in Cyanotic Heart Disease : Mechanisms and Therapies ». Dans Inflammatory Response in Cardiovascular Surgery, 349–53. London : Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-4429-8_41.
Texte intégralZhang-Hoover, Jie, et Joan Stein-Streilein. « Therapies Based on Principles of Ocular Immune Privilege ». Dans Immune Response and the Eye, 317–27. Basel : KARGER, 2007. http://dx.doi.org/10.1159/000099281.
Texte intégralMutchnick, Milton G., J. I. Jaurequi et David A. Shafritz. « Sustained Response to Thymosin Therapy in Patients with Chronic Active Hepatitis B ». Dans Combination Therapies 2, 217–23. Boston, MA : Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_26.
Texte intégralStolfi, Vito M., Jeffrey W. Milsom, James H. Finke, Victor W. Fazio, Luca Ferraris et Claudio Fiocchi. « The Biological Response Modifiers Interleukin-2 and Tumor Necrosis Factor-α Modulate the Cytotoxic Activity of Tumor Infiltrating Lymphocytes Against Human Colon Cancer Cells ». Dans Combination Therapies, 245–51. Boston, MA : Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3340-5_30.
Texte intégralRavagnan, Giampietro, Roberto Falchetti, Paolo Di Francesco, Roberta Gaziano, Giulia Lanzilli, Cartesio Favalli et Enrico Garaci. « Effect of Thymosin α 1 on Cocaine-Induced Inhibition of T-Cell Dependent Murine Immune Response ». Dans Combination Therapies 2, 61–66. Boston, MA : Springer US, 1993. http://dx.doi.org/10.1007/978-1-4615-2964-4_7.
Texte intégralWood, Laura L. « Empirical Research Considerations in Drama Therapy : A Response Essay ». Dans Arts Therapies in Psychiatric Rehabilitation, 155–57. Cham : Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-76208-7_21.
Texte intégralActes de conférences sur le sujet "Response to therapies"
Berceli, Scott A., et Alexander W. Clowes. « Intimal Hyperplasia — Development and Regression in Response to Fluid Shear ». Dans ASME 1999 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 1999. http://dx.doi.org/10.1115/imece1999-0381.
Texte intégralRUSSO, MARIANGELA, Giovanni Crisafulli, Alberto Sogari, Nicole Megan Reilly, Sabrina Arena, Simona Lamba, Alice Bartolini et al. « Abstract A120 : Adaptive mutability of colorectal cancers in response to targeted therapies ». Dans Abstracts : AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ; October 26-30, 2019 ; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a120.
Texte intégralJohnsen, Hannah, Aphrothiti Hanrahan, Alexis Jones et David Solit. « Abstract 36 : Functional characterization of ERBB2 mutations and response to targeted therapies ». Dans Abstracts : AACR Precision Medicine Series : Integrating Clinical Genomics and Cancer Therapy ; June 13-16, 2015 ; Salt Lake City, UT. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pmsclingen15-36.
Texte intégralLAURET, Simon, Laurent Guilleminault, Elise Noel-Savina, Gregoire Prevot, Danielle Brouquieres et Alain Didier. « Are serum immunoglobulins a predictive biomarker of response for anti-IL5 therapies ? » Dans ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.2266.
Texte intégralDunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe et Richard Kennedy. « Abstract 3163 : The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3163.
Texte intégralDunne, Victoria L., Niamh McGivern, Kienan I. Savage, Nuala McCabe et Richard Kennedy. « Abstract 3163 : The role of early response genes (ERG’s) as a biomarker of response to Wee1 targeted therapies ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3163.
Texte intégralBardelli, Alberto. « Abstract PL06-01 : Liquid biopsies to monitor response and resistance to targeted therapies. » Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013 ; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-pl06-01.
Texte intégralPrice, D., E. Sims, L. Kemp, J. von Ziegenweidt, T. Fan et AJ Lee. « Impact of Smoking and Rhinitis on Response to Therapies in Patients with Asthma. » Dans American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5695.
Texte intégralIto, Shuku-ei A., Hidekazu Shirota et Chikashi Ishioka. « Abstract 1454 : IL-4 modulate the tumor microenvironment and response to cancer therapies ». Dans Proceedings : AACR 107th Annual Meeting 2016 ; April 16-20, 2016 ; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1454.
Texte intégralRosa, Rogerio S., Rafael H. S. Santos, Adamo Y. Brito et Katia S. Guimaraes. « Insights on prediction of patients' response to anti-HIV therapies through machine learning ». Dans 2014 International Joint Conference on Neural Networks (IJCNN). IEEE, 2014. http://dx.doi.org/10.1109/ijcnn.2014.6889659.
Texte intégralRapports d'organisations sur le sujet "Response to therapies"
McCawley, Lisa. Breast Cancer Tissue Bioreactor for Direct Interrogation and Observation of Response to Antitumor Therapies. Fort Belvoir, VA : Defense Technical Information Center, juillet 2011. http://dx.doi.org/10.21236/ada552540.
Texte intégralZhu, Zhihong, Yue Zhuo, Haitao Jin, Boyu Wu et Zhijie Li. Chinese Medicine Therapies for Neurogenic Bladder after Spinal Cord Injury : A protocol for systematic review and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, août 2021. http://dx.doi.org/10.37766/inplasy2021.8.0084.
Texte intégralWANG, Xuesong, Xuliang SHI, Jing LV, Juncha ZHANG, Yongli HUO, Guang ZUO, Guangtong LU, Cunzhi LIU et Yanfen SHE. Acupuncture and Related Therapies for anxiety and depression in Diarrhoea-Predominant Irritable Bowel Syndrome(IBS-D) : A Network Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, mars 2022. http://dx.doi.org/10.37766/inplasy2022.3.0162.
Texte intégralFDG-PET/CT SUV for Response to Cancer Therapy, Clinically Feasible Profile. Chair Nathan Hall et Jeffrey Yap. Radiological Society of North America (RSNA) / Quantitative Imaging Biomarkers Alliance (QIBA), juin 2023. http://dx.doi.org/10.1148/qiba/20230615.
Texte intégralShujaa, Asaad Suliman, et Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, novembre 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.
Texte intégralChou, Roger, Rongwei Fu, Tracy Dana, Miranda Pappas, Erica Hart et Kimberly M. Mauer. Interventional Treatments for Acute and Chronic Pain : Systematic Review. Agency for Healthcare Research and Quality (AHRQ), septembre 2021. http://dx.doi.org/10.23970/ahrqepccer247.
Texte intégralSionov, Edward, Nancy Keller et Shiri Barad-Kotler. Mechanisms governing the global regulation of mycotoxin production and pathogenicity by Penicillium expansum in postharvest fruits. United States Department of Agriculture, janvier 2017. http://dx.doi.org/10.32747/2017.7604292.bard.
Texte intégralFamily Therapists Supporting the Hosts of Ukrainian Family (recording). ACAMH, décembre 2022. http://dx.doi.org/10.13056/acamh.21757.
Texte intégralInternet‐delivered cognitive behavior therapy with minimal therapist support for anxious children and adolescents : predictors of response. ACAMH, juin 2020. http://dx.doi.org/10.13056/acamh.12098.
Texte intégral